| 查看: 257 | 回复: 0 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Phase 2 Study Evaluating OGX-427 has Received Grant Funding
|
||
|
OncoGenex Announces that a Randomized, Investigator-Sponsored Phase 2 Study Evaluating OGX-427 has Received Grant Funding BOTHELL, WA and VANCOUVER, BC, Jan. 6, 2010 (Canada NewsWire via COMTEX News Network) -- OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI), today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding. The funds were awarded by a third party granting agency to Dr. Kim Chi, a medical oncologist at the BC Cancer Agency, Research Scientist at the Vancouver Prostate Centre and the principal investigator of the OGX-427 Phase 2 trial. The randomized, controlled Phase 2 study will enroll up to 72 patients and is designed to determine the potential benefit of OGX-427 by evaluating the number of patients who are without disease progression at 12 weeks post study treatment with or without OGX-427. This Phase 2 trial will also measure the direct effect of OGX-427 on PSA levels, time to progression by PSA or measurable disease, numbers of circulating tumor cells (CTCs) and other relevant secondary endpoints. The trial is expected to start by mid 2010 following final analysis of Phase 1 data and approval by Health Canada and the institutional review board. As previously reported, a Phase 1 trial of OGX-427 administered systemically as a single agent to patients with various solid tumors showed reductions in tumor markers associated with prostate and ovarian cancer as well as reductions in total circulating tumor cells. OGX-427 is a second-generation antisense drug that is designed to reduce production of Heat Shock Protein 27 (Hsp27), a cell-survival protein that inhibits treatment-induced cell death through multiple pathways, including the androgen receptor (AR). Preclinical studies have shown that androgen bound to the AR on prostate tumor cells induces rapid Hsp27 phosphorylation that in turn enhances AR activity and prostate cancer cell survival. OGX-427-induced knockdown of Hsp27 led to AR degradation, decreased PSA levels, and delayed progression of castration resistant prostate tumors. |
回复此楼» 猜你喜欢
求助用微谱数据库查询相关文献信息，非常感谢
已经有0人回复
-
考博求助
已经有2人回复
-
药理学论文润色/翻译怎么收费?
已经有222人回复
-
基金评委应该全面采取AI，完美规避人情因素的干扰
已经有2人回复
-
BL21（DE3）出现粗长丝状物
已经有0人回复
-
招聘材料计算，分子动力学模拟合作讲师
已经有10人回复
-
招聘材料计算，分子动力学模拟相关讲师
已经有13人回复
-
25金币微谱求助，谢谢
已经有0人回复
10